Anti-viral material
Manganese oxide with a ramsdellite structure and metal nitrate combination provides a solid antiviral material that efficiently inactivates enveloped viruses by destroying their envelope, addressing the limitations of conventional liquid antiviral materials.
Patent Information
- Application Number
- JP2021140640
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2021-08-31
- Publication Date
- 2024-11-20
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Conventional liquid antiviral materials lose their effectiveness quickly due to evaporation, requiring frequent reapplication and may not be suitable for all surfaces, necessitating a need for solid antiviral materials that maintain efficacy against enveloped viruses like the new coronavirus.
An antiviral material utilizing manganese oxide with a ramsdellite one-dimensional tunnel structure, combined with a metal nitrate, providing a high specific surface area and pore volume, effectively inactivates viruses by destroying their envelope, even in a solid state.
The antiviral material effectively inactivates viruses, particularly enveloped viruses, in a short time and maintains antiviral properties without frequent reapplication, offering a sustainable solution.
Smart Images

Figure 2024161630000001 
Figure 2024161630000002
Abstract
Description
[Technical field]
[0001] The present invention relates to an antiviral material. [Background technology]
[0002] As an antiviral agent (antiviral material), for example, molybdenum oxide (MoO 3 ) as an active ingredient is known (see Patent Document 1). [Prior art documents] [Patent documents]
[0003] [Patent Document 1] JP 2019-118465 A Summary of the Invention [Problem to be solved by the invention]
[0004] There is a demand for antiviral materials that can effectively inactivate viruses, particularly antiviral materials for enveloped viruses such as the novel coronavirus, the spread of which has become a cause for concern in recent years.
[0005] However, in the case of a liquid antiviral material containing an active ingredient, for example, ethanol, which has been conventionally used, if the active ingredient evaporates from the surface to which it is applied, the antiviral properties are lost and the effect does not last, so it is necessary to repeatedly spray or apply the material to the object to be treated. In addition, there is a concern that the material may deteriorate depending on the material of the object to be treated, so application itself may be difficult. Therefore, there is a strong demand for an antiviral material that has excellent antiviral properties that can efficiently inactivate viruses in a short time and can maintain its antiviral properties in a solid state. [Means for solving the problem]
[0006] The present inventors have conducted extensive research to solve the above problems, and have found that the above problems can be solved by using manganese oxide having a specific crystal structure, thereby completing the present invention.
[0007] That is, the present invention provides the following [1] to
[16] . [1] An antiviral material comprising manganese oxide, the crystal structure of which is a ramsdellite-type one-dimensional tunnel structure. [2] The specific surface area of the manganese oxide is 210 m 2 / g~250m 2 / g. The antiviral material according to [1]. [3] The total pore volume of the manganese oxide is 0.15 cm 3 / g~0.35cm 3 / g. The antiviral material according to [1] or [2]. [4] The antiviral material according to any one of [1] to [3], wherein the manganese oxide is manganese dioxide. [5] The antiviral material according to any one of [1] to [4], comprising a carrier containing the manganese oxide and a metal nitrate. [6] The antiviral material according to [5], wherein the metal nitrate is silver nitrate. [7] The antiviral material according to [5] or [6], wherein the content of the metal nitrate relative to the mass of the antiviral material is 5.5% by mass to 20% by mass. [8] The antiviral material according to any one of [1] to [7], which is for use against enveloped viruses. [9] A method for removing airborne viruses, comprising a step of contacting the antiviral material according to any one of [1] to [8] with air containing airborne viruses.
[10] A filter comprising the antiviral material according to any one of [1] to [8].
[11] An air purifier comprising the filter described in
[10] .
[12] An air conditioner comprising the filter according to
[10] .
[13] A refrigerator comprising the filter according to
[10] .
[14] A building material comprising the antiviral material according to any one of [1] to [8].
[15] A container comprising the antiviral material according to any one of [1] to [8].
[16] An automobile interior material comprising the antiviral material according to any one of [1] to [8]. Effect of the Invention
[0008] According to the present invention, it is possible to provide an antiviral material that can effectively inactivate viruses in a short period of time even in a solid state. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] An antiviral material according to an embodiment of the present invention will be described below. The present invention is not limited to the following embodiment, and can be appropriately modified without departing from the gist of the present invention.
[0010] 1. Antiviral materials The antiviral material of the present embodiment contains manganese oxide, and the crystal structure of the manganese oxide is a ramsdellite-type one-dimensional tunnel structure. Hereinafter, components that can be contained in the antiviral material of the present embodiment will be described.
[0011] (1) Manganese oxide First, the manganese oxide contained in the antiviral material of this embodiment will be described.
[0012] Manganese oxide is usually a porous substance. The crystal structure of manganese oxide is preferably a one-dimensional tunnel structure having a tunnel-like structure with a diameter (circle equivalent diameter) of 0.2 nm to 0.5 nm in an ordered arrangement by the bonding of manganese atoms and oxygen atoms, and more preferably a one-dimensional tunnel structure with a diameter of 0.2 nm to 0.3 nm. Examples of manganese oxide having a one-dimensional tunnel crystal structure include cryptomelane, pyrolusite, and ramsdellite. Here, the crystal structure of cryptomelane is called α type, and the crystal structure of pyrolusite is called β type.
[0013] The crystal structure of Ramsdellite is called the ramsdellite type (R type). In the ramsdellite type, a structure in which the ordered arrangement of manganese and oxygen atoms is further distorted is called the γ type. In addition, in the ramsdellite type, a structure containing oxygen atom defects is also called the ε type. Thus, the ramsdellite type includes the λ type and the ε type.
[0014] In the ramsdellite-type manganese oxide applied to the antiviral material of this embodiment, the crystal structure has a ramsdellite-type one-dimensional tunnel structure as already described. More specifically, in this embodiment, the one-dimensional tunnel structure of manganese oxide has a tunnel with a diameter (circle equivalent diameter) of about 0.23 nm in the b-axis direction, and more preferably has a tunnel with a diameter of about 0.2 nm in the orthogonal a-axis direction. Manganese oxide having a ramsdellite-type one-dimensional tunnel structure is usually a particle with a particle size of 1 nm to 5 nm.
[0015] In the antiviral material of this embodiment, the manganese oxide is preferably contained as aggregated particles formed by aggregating a plurality of particles. Specifically, the manganese oxide is preferably contained as aggregated particles formed by aggregating a plurality of manganese oxide particles and including one or more pores (pores) having a diameter of 2 nm to 10 nm.
[0016] In this embodiment, the specific surface area S (unit: m 2 / g) is preferably 210m 2 / g~250m 2 / g, more preferably 215m 2 / g~235m 2 / g.
[0017] The specific surface area of manganese oxide can be measured using any suitable conventionally known measuring device based on a nitrogen adsorption method.
[0018] In this embodiment, the total pore volume V (unit: cm 3 / g) is preferably 0.15 cm 3 / g~0.35cm 3 / g, more preferably 0.18 cm 3 / g~0.30cm 3 / g, and more preferably 0.20 cm 3 / g~0.25cm 3 / g.
[0019] The total pore volume of manganese oxide can be measured using any suitable conventionally known measuring device based on a nitrogen adsorption method.
[0020] In this embodiment, the particle size of the manganese oxide agglomerated particles is preferably 10 μm or less, and more preferably 0.1 μm to 5 μm.
[0021] The particle size of the manganese oxide particles and the aggregate particles formed by agglomerating a plurality of manganese oxide particles can be measured based on observation with a transmission electron microscope or a scanning electron microscope.
[0022] In the antiviral material of this embodiment, the manganese oxide may be, for example, manganese monoxide (MnO), manganese dioxide (MnO 2 ), manganese trioxide (Mn 2 O 3 ), Manganese tetraoxide (Mn 3 O 4 ) In the antiviral material of the present embodiment, the manganese oxide is preferably manganese dioxide. That is, in the antiviral material of the present embodiment, the manganese oxide is preferably manganese dioxide whose crystal structure is a ramsdellite-type one-dimensional tunnel structure.
[0023] In this embodiment, the manganese oxide contained in the antiviral material may be manganese oxide produced as described below, or may be commercially available manganese oxide.
[0024] In the antiviral material of the present embodiment, by using manganese dioxide having a ramsdellite-type one-dimensional tunnel structure as the manganese oxide, it is possible to provide an antiviral material that can effectively inactivate viruses in a short period of time and sustainably maintain antiviral activity even in a solid state, at a lower cost.
[0025] The antiviral material of the present embodiment preferably contains manganese oxide in an amount of 50% by mass or more, that is, 50% to 100% by mass, and more preferably 70% to 100% by mass.
[0026] In this embodiment, "antiviral properties" refers to a function of inactivating a virus that comes into contact with the antiviral material by causing it to lose at least a portion of its function, thereby rendering the virus inactive. More specifically, "antiviral properties" refers to a function of acting on a virus to render the virus inactive, for example, by causing it to lose its ability to invade host cells and its ability to grow. In particular, when the virus is an enveloped virus, the antiviral material of this embodiment can exert its antiviral properties by destroying the viral envelope, thereby rendering it unable to invade host cells.
[0027] The antiviral material of the present embodiment may contain substances (compounds) other than manganese oxide, provided that the action and effect of the antiviral material is not impaired. Examples of compounds other than manganese oxide that may be contained in the antiviral material include iron oxide, silicon dioxide, sulfate ions, alkali metals, and water.
[0028] The compounds other than manganese oxide contained in the manganese oxide-containing carrier and their contents can be adjusted, for example, by appropriately changing the conditions for the production method of manganese oxide.
[0029] (2) Metal nitrates The antiviral material of the present embodiment may further contain a metal nitrate salt in addition to the manganese oxide already described. In this case, it is preferable that the manganese oxide is contained as a carrier. That is, the antiviral material of the present embodiment may contain a carrier containing manganese oxide and a metal nitrate salt.
[0030] In this embodiment, the term "carrier" refers to a substance that has a function of being able to support a functional substance on its surface in a highly dispersed state. In the antiviral material of this embodiment, the manganese oxide contained as the carrier itself can also exhibit antiviral properties.
[0031] In the antiviral material of the present embodiment, it is believed that the metal nitrate exhibits antiviral properties against viruses through a mechanism different from that of the "manganese oxide" already described.
[0032] Therefore, if the antiviral material of the present embodiment is configured to further contain a metal nitrate salt in addition to manganese oxide, it can exhibit antiviral properties that can inactivate viruses more effectively in a shorter period of time even in a solid state.
[0033] In the present embodiment, examples of the metal nitrate include silver nitrate, iron nitrate, cerium nitrate, nickel nitrate, copper nitrate, and aluminum nitrate. Of these, it is preferable to use silver nitrate as the metal nitrate.
[0034] The content of the metal nitrate in the antiviral material of the present embodiment is preferably 5.5% by mass to 20% by mass, more preferably 6% by mass to 15% by mass, and further preferably 7% by mass to 10% by mass.
[0035] In order to adjust the content of the metal nitrate in the antiviral material of the present embodiment to fall within the above range, the ratio of the metal nitrate to the carrier is appropriately adjusted when the metal nitrate is supported on the carrier containing manganese oxide. The content of the metal nitrate can be measured, for example, by inductively coupled plasma mass spectrometry (ICP-MS).
[0036] 2. Usage of antiviral materials The application of the antiviral material of the present embodiment is not particularly limited. The antiviral material of the present embodiment can be used, for example, by being provided as a solidified film or attached to the surface of an article or a component thereof that requires antiviral properties.
[0037] Specifically, the antiviral material of the present embodiment can be suitably applied to air purifiers, air conditioners, refrigerators, building materials, containers, and automobile interior materials made of, for example, fibers, nonwoven fabrics, filters, films, plastic resin materials, concrete, mortar, tiles, glass, or the like.
[0038] The material of the filter is not particularly limited, and may be, for example, a filter material such as a honeycomb, filter paper, nonwoven fabric, or cloth containing an antiviral material, or a structure in which the antiviral material is filled in a space constituted by a breathable material such as filter paper, nonwoven fabric, or cloth.
[0039] When a filter equipped with the antiviral material of the present embodiment is used in an air purifier, an air conditioner, or a refrigerator, it can be used in combination with a known adsorbent for volatile organic compounds. The type of adsorbent is not particularly limited, but for example, activated carbon, silica gel, diatomaceous earth, zeolite, etc. can be used, and among them, activated carbon is preferred.
[0040] In order for the antiviral material of this embodiment to exhibit its antiviral properties, it is necessary for it to be in contact with the atmosphere (air). Therefore, the antiviral material of this embodiment is preferably provided so as to be exposed on the surface of an article requiring antiviral properties and to be in contact with the atmosphere.
[0041] Specifically, the antiviral material of the present embodiment is preferably provided so as to cover a part or all of an exposed surface of the above-mentioned article or a component thereof, particularly a surface that is expected to come into contact with air containing viruses, or so as to be exposed from a part or all of the surface.
[0042] Specifically, for example, a suspension (slurry) is prepared by dispersing the antiviral material in a predetermined dispersion medium, and the suspension is applied to the surface of the above-mentioned article to form, for example, a layer-like coating film on the surface of the article, which is then subjected to a drying treatment (heat treatment) to provide it as a solidified film; alternatively, the dispersion medium is removed and only the antiviral material is attached and fixed to the surface of the article, thereby providing the antiviral material so that part or all of the surface of the article is exposed.
[0043] Here, examples of the dispersion medium include water and ethanol. It is preferable to use water as the dispersion medium, and particularly when a solidified film is to be formed, it is preferable to use water as the dispersion medium. As the water that can be used as the dispersion medium, it is preferable to use water with a higher purity such as distilled water, ion-exchanged water, and ultrapure water.
[0044] When preparing a suspension in which the antiviral material of the present embodiment is dispersed, a known binder may be used. The material and method of use of the binder are not particularly limited as long as they do not inhibit the contact between the antiviral material of the present embodiment and the virus. Examples of the binder material include inorganic binders and organic binders. Examples of the inorganic binder include oxides such as silica particles, alumina particles, and titania particles, sols of these oxides, sodium alginate, and ammonium nitrate.
[0045] The organic binder is not particularly limited, but examples thereof include (meth)acrylic acid ester resins, vinyl acetate resins, ethylene-vinyl ester copolymer resins, vinyl acetate-(meth)acrylic acid copolymer resins, epoxy resins, phenolic resins, fluororesins, methyl cellulose, and ethyl cellulose.
[0046] When preparing a suspension containing manganese oxide or manganese oxide carrying a metal nitrate as an antiviral material and a dispersion medium, the content of manganese oxide or manganese oxide carrying a metal nitrate can be any suitable content taking into consideration the use of the article to which the antiviral material is applied, etc. The content of manganese oxide or manganese oxide carrying a metal nitrate in the suspension is preferably 50 mass% or less, more preferably 25 mass% or less, and even more preferably 10 mass% or less.
[0047] The method of applying the suspension and the method of forming the coating film are not particularly limited. Any suitable conventionally known coating method can be applied to apply the suspension and form the coating film. When using the antiviral agent of the present embodiment, it is preferable to apply a dipping coating method, a spray coating method, or a roll coating method as the coating method. After application, it is preferable to dry at a temperature of 150° C. or less. The atmosphere during drying is not particularly limited, but it is preferable to perform, for example, an air atmosphere or an inert gas atmosphere.
[0048] The amount of manganese oxide present on the surface of the article to which the antiviral material of this embodiment is applied is usually 0.1 g / m 2 ~200g / m 2 and 1 g / m 2 ~100g / m 2 It is preferable to set the thickness to 5 g / m 2 ~50g / m 2 It is more preferable to set the above.
[0049] When the antiviral material of this embodiment contains manganese oxide carrying a metal nitrate, the amount of manganese oxide carrying a metal nitrate on the surface of the article to which it is applied is usually 0.1 g / m 2 ~200g / m 2 and 1 g / m 2 ~100g / m 2 It is preferable to set the thickness to 5 g / m 2 ~50g / m 2 It is more preferable to set the above.
[0050] The antiviral material of this embodiment can also be configured integrally with the above-mentioned article. Specifically, the antiviral material of this embodiment can be mixed with the raw material of the article and processed, such as by molding, to be configured integrally so that the antiviral material is exposed on at least a part of the surface of the article. In this case, the amount of the antiviral material of this embodiment added to the raw material of the article can be determined taking into consideration the shape, size, color, and the like of the article to be manufactured, provided that antiviral properties can be exhibited.
[0051] The antiviral material of this embodiment exerts antiviral properties when exposed to the atmosphere (air), and inactivates viruses that come into contact with the antiviral material by, for example, destroying the envelope, thereby causing at least a portion of the function to be lost, thereby rendering the viruses inactive. Thus, the antiviral properties can be restored by removing the inactivated viruses from the surface of the antiviral material (the article to which the antiviral material is applied). To restore the antiviral properties of the antiviral material of this embodiment, further treatment, for example, heat treatment, may be performed.
[0052] The antiviral material of the present embodiment can be regenerated by a simple process as described above, and can stably maintain the expression of antiviral activity for a long period of time without the need for repeated application as is required for volatile antiviral materials.
[0053] The type of virus to which the antiviral material of the present embodiment can be suitably applied is not particularly limited. The antiviral material of the present embodiment can be applied to, for example, both enveloped viruses and non-enveloped viruses.
[0054] Examples of viruses to which the antiviral material of the present embodiment can be suitably applied include enveloped viruses such as coronavirus, influenza virus, herpes virus, porcine coronavirus, and bovine coronavirus, and non-enveloped viruses such as norovirus, rotavirus, and feline calicivirus.
[0055] The antiviral material of the present embodiment is preferably for use against enveloped viruses.
[0056] 3. Preparation of Antiviral Materials The crystal structure of manganese oxide that can be contained in the antiviral material can be adjusted by appropriately changing the conditions for the production process (preparation process) of manganese oxide.
[0057] Manganese oxide can be produced by any suitable conventionally known production method, such as an electrolysis method, a hydrothermal synthesis method, or an oxidative heat treatment method.
[0058] When manganese oxide is produced by hydrothermal synthesis, the crystal structure of manganese oxide can be adjusted, for example, by appropriately adjusting the concentration of the manganese salt raw material contained in the precursor liquid for hydrothermal synthesis, the coexisting cations contained in the precursor liquid for hydrothermal synthesis, and the pH of the precursor liquid for hydrothermal synthesis.
[0059] The crystal structure of manganese oxide is described in the literature (S. Devaraj, et al., "Effect of Crystallographic Structure of MnO 2 on Its Electrochemical Capacitance Properties”, The Journal of Physical Chemistry C, 2008, 112, 4406), it can be identified by powder X-ray diffraction method.
[0060] The specific surface area of manganese oxide can be adjusted by the heat treatment conditions in the manganese oxide production process, specifically, for example, by the type of gas used in the heat treatment of manganese oxide and the heat treatment temperature of manganese oxide.
[0061] The total pore volume of manganese oxide can be adjusted by the heat treatment conditions in the manganese oxide production process, for example, by appropriately changing the type of gas used in the heat treatment of manganese oxide and the heat treatment temperature of manganese oxide.
[0062] In the present embodiment, when the antiviral material contains manganese oxide supporting a metal nitrate, examples of a method for supporting the metal nitrate on a carrier containing manganese oxide include a method of contacting manganese oxide with a solution containing the metal nitrate.
[0063] Specific examples of methods for contacting manganese oxide with a solution containing a metal nitrate include a method in which a support is impregnated with a solution containing the metal nitrate (impregnation method), a method in which a support is immersed in a solution containing the metal nitrate to adsorb the metal nitrate (immersion method), and an ion exchange method.
[0064] As conditions for the contact treatment, the temperature of the contact treatment is preferably 0° C. to 100° C., more preferably 0° C. to 50° C. The pressure of the contact treatment is preferably atmospheric pressure (0.1 MPaA) to 1 MPaA, more preferably atmospheric pressure. The atmosphere of the contact treatment can be an inert gas atmosphere such as air, nitrogen gas, helium gas, argon gas, carbon dioxide gas, etc., and the inert gas atmosphere may further contain water vapor.
[0065] The solution containing the metal nitrate can be prepared by mixing the metal nitrate with any suitable solvent.
[0066] Examples of the solvent include water and alcohols such as ethanol. Among these, water is preferred as the solvent. From the viewpoint of suppressing a decrease in antiviral properties due to impurities adhering to the metal nitrate and, in turn, to the antiviral material, it is preferred to use highly pure water such as distilled water, ion-exchanged water, and ultrapure water as the water solvent.
[0067] When producing an antiviral material further containing a metal nitrate, it is preferable to carry out a drying step after the metal nitrate is supported on the carrier containing manganese oxide as described above.
[0068] The drying step may be carried out by a conventional method. The drying temperature in the drying step is preferably from room temperature to 100° C., and the pressure in the drying step is preferably from 0.001 MPaA to 1 MPaA, more preferably atmospheric pressure. The atmosphere in the drying step may be an inert gas atmosphere such as air, nitrogen gas, helium gas, argon gas, or carbon dioxide gas, and the inert gas atmosphere may further contain water vapor. EXAMPLES
[0069] EXAMPLES Hereinafter, examples of the present invention will be described, but the present invention is not limited to the examples described below.
[0070] (specific surface area) Specific surface area of manganese oxide (manganese dioxide) (unit: m 2 / g) was measured by the BET multipoint method using the nitrogen adsorption method. The specific surface area was measured using a BELSORP-mini (manufactured by BEL Japan Co., Ltd.) as a measuring device.
[0071] Specifically, first, the nitrogen adsorption isotherm of manganese oxide was created at an adsorption temperature of 77 K (-196°C).
[0072] The specific surface area of manganese oxide was then calculated from the created nitrogen adsorption isotherm in the relative pressure range of 0.05 to 0.35 using the BET multipoint method.
[0073] (total pore volume) Total pore volume of manganese oxide (unit: cm 3 / g) was calculated from the value of the adsorption amount of nitrogen molecules at a relative pressure of 0.98 in the nitrogen adsorption isotherm created as described above.
[0074] (Cell cultures and test viruses) The cultured cells used were vero cells (a cell line derived from the kidney epithelium of African green monkeys). The cultured cells were cultured according to standard methods using Sigma-Aldrich MEM medium (containing fetal bovine serum (5%)) as a cell maintenance medium. The test virus used was the P-5V strain of Porcine epidemic diarrhea virus (PEDV), an enveloped virus, obtained from Nichiseiken Co., Ltd.
[0075] [Example 1] Manganese dioxide (MnO) has a ramsdellite-type one-dimensional tunnel structure (ε-type) crystal structure. 2 ) (Japan Metals and Chemicals Co., Ltd., AMD250, specific surface area: 226 m 2 / g, total pore volume: 0.22 cm 3 The aggregated particles (particle diameter: 0.2 to 10 μm) formed by agglomerating particles (particle diameter: 1 to 5 nm) of MnO (1.0 μm x 10 μm) containing 100 μm of MnO2 (1.0 μm x 10 μm) were used as the antiviral material (1). 2 The crystal structure, specific surface area, and total pore volume are also shown in Table 1 below.
[0076] <Antiviral test> Antiviral tests were performed in accordance with ISO18184 and ISO21702. Specifically, a suspension (slurry) of the above antiviral material (1) in purified water at a 10-fold volume was applied to a nonwoven fabric with a side length of 5 cm, and the fabric was dried at room temperature to prepare a test piece 1.
[0077] 0.4 mL of a liquid containing the test virus (containing the previously explained porcine epidemic coronavirus P-5V strain, MEM medium, and fetal bovine serum) was added to the obtained test piece 1, and the test piece 1 was covered with a sterilized film, sealed, and left to stand in the dark at room temperature for a specified time. This specified time was the sensitization time.
[0078] After the sensitization time had elapsed, the test piece 1 was removed from the sterilization film and placed in a sterilization bag. Then, 20 mL of cell maintenance medium was added to the sterilization bag, and the bag was shaken to mix and wash out the virus, thereby obtaining a washout solution.
[0079] The resulting washout solution was then centrifuged at 2500 rpm for 5 minutes.
[0080] The supernatant obtained by centrifugation, which may contain the test virus, was further serially diluted 10-fold using the cell maintenance medium. Each of the resulting dilutions (1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, and 10-fold) was inoculated onto cultured cells contained in wells of a 96-well microplate, and then incubated at 37 °C for 1 h in 5% CO 2 The cultured cells were infected with the test virus by culturing them in the presence of gas at 37°C for 5 days.
[0081] Next, using the cell degeneration (change in shape) caused by infection of the cultured cells with the test virus as an index, the amount of test virus remaining even after sensitization with test piece 1 was calculated as the 50% tissue culture infectivity titer (TCID50) by the plaque method.
[0082] <Antiviral activity value> Based on the calculated TCID50, the antiviral activity value was calculated. Specifically, the antiviral activity value was calculated according to the following formula. The results are shown in Table 2 below. Formula: Antiviral activity value = common logarithm of 50% tissue culture infectivity of control test specimen - common logarithm of 50% tissue culture infectivity of test specimen
[0083] [Comparative Example 1] An antiviral test was carried out in the same manner as in Example 1, except that Comparative Test Piece 1, which was a control test piece in which no antiviral material was applied to the nonwoven fabric, was prepared and used instead of Test Piece 1, and the antiviral activity value was calculated. The results are shown in Table 2 below.
[0084] [Table 1]
[0085] [Table 2]
[0086] As is clear from Table 2 above, it was found that the antiviral material of this example can effectively inactivate viruses (especially enveloped viruses) in a short period of time.
Claims
1. An antiviral material comprising manganese oxide, the crystal structure of which is a ramsdellite-type one-dimensional tunnel structure.
2. The specific surface area of the manganese oxide is 210 m 2 / g~250m 2 The antiviral material according to claim 1, wherein the antiviral activity is 1 / g.
3. The total pore volume of the manganese oxide is 0.15 cm 3 / g ~ 0.35 cm 3 The antiviral material according to claim 1 or 2, wherein the antiviral activity is 100% or more.
4. The antiviral material according to any one of claims 1 to 3, wherein the manganese oxide is manganese dioxide.
5. The antiviral material according to any one of claims 1 to 4, comprising a carrier containing the manganese oxide and a metal nitrate.
6. The antiviral material according to claim 5, wherein the metal nitrate is silver nitrate.
7. The antiviral material according to claim 5 or 6, wherein the content of the metal nitrate relative to the mass of the antiviral material is 5.5% by mass to 20% by mass.
8. The antiviral material according to any one of claims 1 to 7, which is for use against enveloped viruses.
9. A method for removing airborne viruses, comprising a step of contacting the antiviral material according to any one of claims 1 to 8 with air containing airborne viruses.
10. A filter comprising the antiviral material according to any one of claims 1 to 8.
11. An air purifier comprising the filter of claim 10.
12. An air conditioner comprising the filter of claim 10.
13. A refrigerator comprising the filter of claim 10.
14. A building material comprising the antiviral material according to any one of claims 1 to 8.
15. A container comprising the antiviral material according to any one of claims 1 to 8.
16. An automobile interior material comprising the antiviral material according to any one of claims 1 to 8.
Citation Information
Patent Citations
Holding structure of chair cover member and chair equipped with the same
JP2019118465A
